Every Form 4 that PETROS PHARM INC (PTPI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PTPI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PTPI filings page.
WALKER WAYNE REMELL reported acquisition or exercise transactions in this Form 4 filing.
Petros Pharmaceuticals director Wayne Remell Walker received an equity grant of company stock. He was awarded 375,000 restricted shares of Petros Pharmaceuticals common stock at no cash cost. According to the terms, 50% of these shares vested on the grant date and the remaining 50% will vest six months later if he is still providing services to the company at that time. Following this grant, he directly holds a total of 881,333 common shares.
Boctor Fady reported acquisition or exercise transactions in this Form 4 filing.
Petros Pharmaceuticals, Inc. reported that officer Fady Boctor received a grant of 375,000 shares of common stock as equity compensation. The filing states that 50% of these restricted shares vested on the grant date, while the remaining 50% will vest after six months if he continues providing services, bringing his direct holdings to 894,986 shares.
Bernstein Bruce reported acquisition or exercise transactions in this Form 4 filing.
Petros Pharmaceuticals director Bruce Bernstein received a grant of 1,875,000 restricted shares of common stock. The shares were awarded at a price of $0.00 per share as equity compensation. After this grant, he directly holds 3,762,334 common shares.
According to the terms, 50% of the restricted shares vested on the grant date and the remaining 50% will vest on the six-month anniversary of the grant, provided he is still providing services to the company at that time.
Silverman Joshua reported acquisition or exercise transactions in this Form 4 filing.
Petros Pharmaceuticals director Joshua Silverman reported receiving a large stock award in the form of restricted common shares. He was granted 4,375,000 shares of Petros Pharmaceuticals common stock as a grant or award, rather than an open-market purchase.
According to the terms, 50% of these restricted shares vested on the grant date, while the remaining 50% will vest six months after the grant date if he is still providing services to the company at that time. Following this grant, Silverman directly holds a total of 8,790,450 shares of Petros Pharmaceuticals common stock.
Petros Pharmaceuticals, Inc. reported an equity grant to one of its senior executives. Officer Fady Boctor, who serves as President & Chief Commercial Officer, received 500,000 restricted stock units (RSUs) of Petros common stock on 01/02/2026 at a stated price of $0 per unit.
According to the terms, 50% of these RSUs vested on the grant date, and the remaining 50% will vest on the six‑month anniversary of the grant date if he is still providing services to the company. Each RSU gives the right to receive one share of common stock. After this grant, Boctor beneficially owned 519,986 shares of Petros common stock, with amounts adjusted for the company’s 1‑for‑25 reverse stock split that became effective at 4:05 p.m. New York time on April 30, 2025.
Petros Pharmaceuticals, Inc. director Joshua Silverman reported a new equity award in the company’s common stock. On 01/02/2026, he received 4,375,000 restricted stock units (RSUs) at a price of $0, reflecting a compensatory grant. Half of these RSUs vested on the grant date, and the remaining half will vest on the six‑month anniversary of the grant, provided he continues providing services to the company.
Each RSU represents the right to receive one share of common stock with a par value of $0.0001 per share. Following this transaction, Silverman beneficially owned 4,415,450 shares of Petros Pharmaceuticals common stock directly. The reported amounts have been adjusted to reflect the company’s 1‑for‑25 reverse stock split of its common stock that became effective at 4:05 p.m. New York time on April 30, 2025.
Petros Pharmaceuticals, Inc. reported an equity award to a director on a Form 4. On 01/02/2026, a director received 500,000 restricted stock units (RSUs) of Petros Pharmaceuticals common stock at a stated price of $0 per unit. According to the filing, 50% of the RSUs vested on the grant date and the remaining 50% will vest on the six-month anniversary of the grant date, as long as the director continues providing services to the company on that vesting date. Each RSU corresponds to one share of common stock. Following this grant, the director is reported to beneficially own 506,333 shares of Petros Pharmaceuticals common stock. The filing notes that these share amounts have been adjusted for the company’s 1-for-25 reverse stock split that became effective on April 30, 2025.
Petros Pharmaceuticals, Inc. reported that a director acquired additional equity through a stock-based compensation grant. On 01/02/2026, the reporting person received 1,875,000 Restricted Stock Units (RSUs) of Petros common stock at a price of $0 per unit, recorded as an acquisition. Following this grant, the director beneficially owns 1,887,334 shares of common stock in direct ownership.
The filing explains that 50% of the RSUs vested on the grant date and the remaining 50% will vest on the six-month anniversary of the grant, provided the director is still providing services to the company at that time. Each RSU converts into one share of common stock. The share amounts in the filing have been adjusted to reflect the company’s previously effected 1-for-25 reverse stock split of its common stock.